{
  "id": "ngn_matrix_mission_500_175_1771352447039",
  "itemType": "matrixMatch",
  "caseTitle": "35-Week Gestation with Worsening Preeclampsia",
  "prompt": "The nurse is reviewing the client's electronic health record. For each finding below, click to specify if the finding is most consistent with the progression of HELLP syndrome or indicative of magnesium sulfate toxicity. Each finding supports only one category.",
  "tabs": [
    {
      "id": "nursesNotes",
      "title": "Nurses' Notes",
      "content": "<strong>1800:</strong> Client is a 32-year-old G1P0 female at 35 weeks gestation admitted from an outpatient clinic with a BP of 172/114 mmHg, 3+ proteinuria, and severe headache. Client reports inconsistent prenatal care due to recent immigration and transportation challenges. Antecubital 18-gauge IV started. Magnesium sulfate 4g loading dose administered over 20 minutes, maintenance infusion started at 2 g/hr. Labetalol 20 mg IV given. Client is on continuous fetal monitoring.\n\n<strong>2200:</strong> Client reports feeling 'woozy and hot all over' and that her 'breathing feels heavy.' States vision is blurry. Rates epigastric pain as a dull ache, 8/10. Client appears flushed and is slow to respond to questions. Partner at bedside appears anxious. Deep tendon reflexes (DTRs) assessed and are 0/4 bilaterally. Urine output via indwelling catheter 20 mL in the last hour."
    },
    {
      "id": "vitalSigns",
      "title": "Vital Signs",
      "content": [
        {
          "time": "1800",
          "BP": "172/114",
          "HR": "92",
          "RR": "18",
          "SpO2": "98%",
          "Temp": "37.1°C (98.8°F)"
        },
        {
          "time": "2000",
          "BP": "158/102",
          "HR": "88",
          "RR": "16",
          "SpO2": "97%",
          "Temp": "37.2°C (99.0°F)"
        },
        {
          "time": "2200",
          "BP": "150/98",
          "HR": "84",
          "RR": "10",
          "SpO2": "93%",
          "Temp": "37.1°C (98.8°F)"
        }
      ]
    },
    {
      "id": "labResults",
      "title": "Laboratory Results",
      "content": {
        "Test": "Result",
        "Platelet Count": "75,000/mm³ (Low)",
        "Aspartate aminotransferase (AST)": "250 U/L (High)",
        "Alanine aminotransferase (ALT)": "180 U/L (High)",
        "Serum Creatinine": "1.4 mg/dL (High)",
        "Serum Magnesium": "9.1 mEq/L (Critical High)"
      }
    }
  ],
  "matrixMatchData": {
    "rows": [
      "Respiratory rate of 10/min",
      "Platelet count of 75,000/mm³",
      "Urine output of 20 mL/hr",
      "Absent patellar reflexes (0/4)",
      "Epigastric pain 8/10",
      "Serum magnesium level 9.1 mEq/L"
    ],
    "columns": [
      "Consistent with HELLP Syndrome Progression",
      "Indicative of Magnesium Sulfate Toxicity"
    ]
  },
  "answer": [
    {
      "row": 0,
      "column": 1
    },
    {
      "row": 1,
      "column": 0
    },
    {
      "row": 2,
      "column": 0
    },
    {
      "row": 3,
      "column": 1
    },
    {
      "row": 4,
      "column": 0
    },
    {
      "row": 5,
      "column": 1
    }
  ],
  "answerBreakdown": [
    {
      "row": "Respiratory rate of 10/min",
      "column": "Indicative of Magnesium Sulfate Toxicity",
      "rationale": "Correct. Magnesium sulfate is a central nervous system (CNS) depressant. A respiratory rate less than 12 breaths/minute indicates CNS depression due to hypermagnesemia. Magnesium blocks calcium channels, reducing acetylcholine release at the neuromuscular junction, leading to muscle weakness and respiratory depression. Severe toxicity can lead to respiratory arrest.",
      "clinicalPearl": "Closely monitor respiratory rate, depth, and effort in patients receiving magnesium sulfate. Have calcium gluconate readily available to reverse respiratory depression.",
      "pathophysiology": "Magnesium sulfate toxicity causes CNS depression by blocking calcium channels, inhibiting neurotransmitter release, and reducing neuronal excitability. This leads to decreased respiratory drive and muscle weakness."
    },
    {
      "row": "Platelet count of 75,000/mm³",
      "column": "Consistent with HELLP Syndrome Progression",
      "rationale": "Correct. HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) is characterized by thrombocytopenia (platelet count <100,000/mm³). Platelet consumption occurs due to endothelial damage and activation of the coagulation cascade in the liver. This finding indicates worsening HELLP syndrome.",
      "clinicalPearl": "Serial platelet counts are crucial in monitoring HELLP syndrome progression. A rapidly declining platelet count indicates severe disease and increased risk of complications.",
      "pathophysiology": "In HELLP syndrome, widespread endothelial damage activates the coagulation cascade, leading to platelet aggregation and consumption in the microvasculature of the liver. This results in thrombocytopenia and impaired clotting ability."
    },
    {
      "row": "Urine output of 20 mL/hr",
      "column": "Consistent with HELLP Syndrome Progression",
      "rationale": "Correct. Oliguria (urine output <30 mL/hr) is a sign of worsening preeclampsia/HELLP due to intense vasospasm and reduced renal perfusion. Preeclampsia causes endothelial dysfunction and vasoconstriction, decreasing blood flow to the kidneys and reducing glomerular filtration rate. This can lead to acute kidney injury.",
      "clinicalPearl": "Strict intake and output monitoring is essential in patients with preeclampsia and HELLP syndrome. Oliguria indicates compromised renal function and necessitates prompt intervention.",
      "pathophysiology": "Preeclampsia-induced vasospasm and endothelial dysfunction reduce renal blood flow and glomerular filtration rate, leading to decreased urine output and potential acute kidney injury. Endothelial damage also increases vascular permeability, contributing to edema and further reducing intravascular volume."
    },
    {
      "row": "Absent patellar reflexes (0/4)",
      "column": "Indicative of Magnesium Sulfate Toxicity",
      "rationale": "Correct. Magnesium sulfate is a CNS depressant that blocks neuromuscular transmission. Loss of deep tendon reflexes (areflexia) is a sign of magnesium toxicity, indicating that serum magnesium levels have exceeded the therapeutic range and are causing neuromuscular blockade. Areflexia typically occurs at magnesium levels of 7-10 mEq/L.",
      "clinicalPearl": "Assess deep tendon reflexes frequently in patients receiving magnesium sulfate. Areflexia is an early sign of magnesium toxicity and warrants immediate intervention.",
      "pathophysiology": "Magnesium sulfate blocks calcium channels at the neuromuscular junction, inhibiting acetylcholine release and impairing muscle contraction. This leads to decreased or absent deep tendon reflexes and muscle weakness."
    },
    {
      "row": "Epigastric pain 8/10",
      "column": "Consistent with HELLP Syndrome Progression",
      "rationale": "Correct. Right upper quadrant or epigastric pain is caused by hepatic swelling and inflammation (periportal necrosis) characteristic of HELLP syndrome. It indicates stretching of Glisson's capsule around the liver and can be a sign of impending liver rupture, a life-threatening complication of HELLP.",
      "clinicalPearl": "Epigastric pain in a patient with preeclampsia should be promptly evaluated for HELLP syndrome and potential liver complications. Palpation of the liver should be avoided to prevent rupture.",
      "pathophysiology": "In HELLP syndrome, fibrin deposition and hepatocellular necrosis cause liver swelling and inflammation. This stretches Glisson's capsule, the fibrous covering of the liver, resulting in right upper quadrant or epigastric pain. Severe cases can lead to liver hematoma or rupture."
    },
    {
      "row": "Serum magnesium level 9.1 mEq/L",
      "column": "Indicative of Magnesium Sulfate Toxicity",
      "rationale": "Correct. The therapeutic range for magnesium sulfate in seizure prophylaxis is typically 4-7 mEq/L. A level of 9.1 mEq/L is critically high and confirms magnesium toxicity. Loss of reflexes occurs around 7-10 mEq/L, respiratory depression at 10 mEq/L, and respiratory arrest can occur at levels >12 mEq/L. This lab value is a definitive contraindication to continuing the infusion.",
      "clinicalPearl": "Regularly monitor serum magnesium levels in patients receiving magnesium sulfate to ensure therapeutic levels and prevent toxicity. Be prepared to administer calcium gluconate if toxicity occurs.",
      "pathophysiology": "Elevated serum magnesium levels cause CNS depression, neuromuscular blockade, and cardiovascular effects. Magnesium blocks calcium channels, inhibiting neurotransmitter release and impairing muscle contraction. This leads to respiratory depression, hypotension, and cardiac arrhythmias."
    }
  ],
  "scoring": {
    "type": "0/1",
    "rationale": "This item uses 0/1 scoring. The student must correctly categorize all six findings to receive credit. This requires differentiating between signs of the primary disease process (HELLP) and the life-threatening iatrogenic complication (magnesium toxicity), which is a critical safety judgment."
  },
  "references": [
    {
      "source": "American College of Obstetricians and Gynecologists (ACOG)",
      "citation": "ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstetrics & Gynecology, 133(1), e1-e25."
    },
    {
      "source": "Perry, S. E., Hockenberry, M. J., Lowdermilk, D. L., & Wilson, D.",
      "citation": "Maternal Child Nursing Care (7th ed.). Elsevier."
    }
  ],
  "cognitiveSkill": "Analyze Cues",
  "clientNeeds": [
    {
      "category": "Physiological Integrity",
      "subcategory": "Reduction of Risk Potential",
      "focus": "Potential for complications from diagnostic tests/treatments/procedures"
    },
    {
      "category": "Safe and Effective Care Environment",
      "subcategory": "Safety and Infection Control",
      "focus": "Error Prevention"
    }
  ],
  "ncsbnClinicalJudgmentMeasurementModel": [
    "Recognize Cues",
    "Analyze Cues"
  ],
  "healthEquity": {
    "hasEquityContent": true,
    "equityRationale": "The scenario includes a client with inconsistent prenatal care due to recent immigration and transportation challenges. These social determinants of health (SDOH) are known risk factors for delayed diagnosis and more severe presentations of hypertensive disorders of pregnancy, highlighting the impact of health disparities on maternal outcomes."
  },
  "sbar": {
    "situation": "32-year-old G1P0 female, 35 weeks gestation, admitted with worsening preeclampsia.",
    "background": "Inconsistent prenatal care due to immigration/transportation issues. Initial BP 172/114 mmHg, 3+ proteinuria, severe headache. Magnesium sulfate 4g load, 2g/hr maintenance, and labetalol 20mg IV initiated.",
    "assessment": "2200 assessment: RR 10/min, platelets 75,000/mm³, urine output 20 mL/hr, absent DTRs, epigastric pain 8/10, Mg level 9.1 mEq/L. Client reports feeling 'woozy and hot all over' and that her 'breathing feels heavy.'",
    "recommendation": "STAT evaluation for magnesium toxicity and HELLP progression. Consider discontinuing magnesium sulfate and administering calcium gluconate. Prepare for potential emergent delivery based on maternal and fetal status. Notify provider immediately."
  },
  "sentinelStatus": "healed_v2026_v8"
}